Stocks · News reference
Morgan Stanley Maintains Overweight on Disc Medicine, Raises Price Target to $92
Morgan Stanley analyst Sean Laaman maintains Disc Medicine (NASDAQ:IRON) with a Overweight and raises the price target from $90 to $92.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Guggenheim Initiates Coverage of Disc Medicine with Buy Rating
Guggenheim Securities has initiated coverage of Disc Medicine, Inc. with a Buy rating and a price target of $132.
Disc Medicine Reports Q3 2026 Financial Results and Operational Progress
Disc Medicine announced its third-quarter 2026 financial results, highlighting the success of the APOLLO trial and a planned NDA resubmission for bitopertin by the end of the year.
Disc Medicine Q3 EPS $(1.53) Beats $(1.76) Estimate
8-K filing — Disc Medicine, Inc. (IRON)
Filed: 2026-11-05 AccNo: 0001193125-26-448711 Size: 1 MB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Premier Miton Group plc Reduces Holding in Ironveld PLC
Premier Miton Group plc has decreased its stake in Ironveld PLC to below 5% following a disposal of voting rights.